Glaucoma 360 New Horizons Forum

Fostering innovation and collaboration to speed the development of new glaucoma therapies and diagnostics.

Glaucoma Research Foundation, the nation’s most experienced nonprofit foundation dedicated solely to glaucoma research and education, will host the 4th Annual Glaucoma 360 New Horizons Forum in San Francisco on February 6, 2015. The meeting focuses on unmet medical needs in glaucoma and brings together the essential elements required to advance into clinical practice new ideas for preventing and managing the disease more effectively.

Cofounded and cochaired by Adrienne Graves, PhD, and Andrew G. Iwach, MD, this annual forum continues to grow and provide the ultimate opportunity for the collaboration and networking needed to speed the translation of new ideas into clinical use to benefit patients.

Dr. Iwach is the executive director of the Glaucoma Center of San Francisco and chairman of the Glaucoma Research Foundation Board. He explained, “The New Horizons Forum has all the necessary partners for expedited innovation in one place—leaders from larger and smaller companies, investors and venture capitalists, physicians, scientists, lawyers, and the FDA—all the key players required to take a new idea to a useful solution for glaucoma patients.”

Dr. Graves added, “For our 2015 program, we are showcasing more than 20 early-stage companies who are developing new glaucoma drugs, devices, drug delivery systems, and diagnostic tools. Our goal is to stimulate and facilitate key discussions and connections to drive the development of new glaucoma therapies.”

John Maroney, president and CEO of ForSight Vision5, remarked that the New Horizons Forum is “a great introduction to emerging technologies in glaucoma and allows you an opportunity to meet and network with innovators and potential funders.”

Jack Elands, CEO of Amakem Therapeutics, will present updated clinical data on his company’s Rho kinase (ROCK) inhibitor in February. He commented, “This is one of the best meetings in the glaucoma field. As a 1-day program, it is short and intense, but because it is so well organized, it is a very effective meeting.”

Each year, more physicians attend the meeting in order to learn firsthand of the emerging technologies that are available now and in the pipeline. Ruth Williams, MD, is president of the Wheaton Eye Clinic and a member of Glaucoma 360’s Steering Committee. She added, “This important and unique meeting is the best place to learn of the promising new therapies, drugs, and devices that can help preserve vision for my patients. The next few years hold exciting possibilities.”

Paul P. Lee, MD, JD, is the F. Bruce Fralick professor and chair of the Department of Ophthalmology and Visual Sciences at the University of Michigan Kellogg Eye Center. He will deliver the Drs. Henry and Frederick Sutro Memorial Lecture to kick-start a full day of presentations and industry panel discussions on innovative developments as well as sessions focused on working with the FDA and securing venture capital funding.

New Horizons Forum is the centerpiece of Glaucoma 360, Glaucoma Research Foundation’s signature 3-day event, which includes the Annual Gala on February 5th to benefit Glaucoma Research Foundation’s research and patient education programs. Dr. Graves will be honored at the Gala for her outstanding leadership and many accomplishments in ophthalmology. Glaucoma 360 closes on February 7th with the Glaucoma Symposium CME, which highlights the latest advances in glaucoma management, medication, and surgical technique for practicing clinicians.

To learn more and register, visit www.glaucoma360.org.